Topic: Parkinson's disease
Eisai and University College London are moving their first candidate into the clinic: a tau-targeting monoclonal antibody for Alzheimer’s disease.
Rheostat Therapeutics raised $23 million to develop treatments for neurodegenerative and rare diseases by targeting the cell’s garbage disposal.
After refocusing on gene therapy, Axovant is appointing five new executives to posts ranging from clinical development to commercial operations.
UCB partners with Verint Systems to launch a new app for Parkinson’s patients.
AbbVie and Mission Therapeutics inked an R&D pact focused on deubiquitylating enzymes in Alzheimer’s and Parkinson’s disease.
UB-312 prevented the accumulation of misfolded alpha-synuclein proteins in cell and animal models of Parkinson's disease.
Protein clumps that occur in both the gut and the brain could be prime targets for Parkinson's therapies, new research suggests.
Pfizer has followed through on its pledge to divest a hunk of its neuroscience R&D, spinning several programs into a new company called Cerevel.
CuraSen Therapeutics has pulled off a $54.5 million series A funding round as it gains big-name backing to help tackle neurodegenerative disorders.